Trial Profile
Multicentre Open Label Non-randomized Clinical Study Evaluating Pharmacokinetics, Safety, Tolerability of Multiple Intravitreal Injections of BCD-021 (CJSC BIOCAD, Russia) in Patients With Neovascular Wet Age-related Macular Degeneration
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 04 Apr 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Age-related macular degeneration
- Focus Adverse reactions
- Sponsors Biocad
- 30 Mar 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Mar 2016 as reported by ClinicalTrials.gov
- 30 Mar 2016 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
- 25 May 2015 New trial record